接受PD-L1抑制剂患者的免疫相关急性肾损伤发生率与临床特征
本研究为回顾性队列研究,纳入2017至2018年接受PD-L1抑制剂治疗的599例患者,评估急性肾损伤(AKI)的发生率、病因及预测因素。结果显示12个月内17%发生AKI,6%为持续性AKI,仅<1%疑似PD-L1相关AKI,中位发生时间99天,且所有疑似病例均同时使用可致急性间质性肾炎的药物。
要点
- PD-L1抑制剂治疗患者中AKI常见(17%),但疑似药物相关AKI罕见(<1%)。
- 疑似PD-L1相关AKI中位发生时间为开始治疗后99天。
- 所有疑似PD-L1相关AKI患者均同时使用质子泵抑制剂、非甾体抗炎药或抗生素。
核心结论
- 接受PD-L1抑制剂治疗的患者中AKI常见,但疑似PD-L1相关AKI发生率低(<1%),可能低于其他类型免疫检查点抑制剂。
研究设计与样本
- 回顾性队列研究,纳入2017至2018年某医疗系统内接受PD-L1抑制剂治疗的599例患者。
主要发现
- 12个月内104例(17%)发生AKI,36例(6%)发生持续性AKI(持续>48小时),仅5例(<1%)疑似PD-L1相关AKI。
- 疑似PD-L1相关AKI的中位发生时间为开始治疗后的99天。
- 所有疑似PD-L1相关AKI患者在当时均同时使用已知可导致急性间质性肾炎的药物(质子泵抑制剂、非甾体抗炎药或抗生素)。
关键数值与推荐
- AKI定义为血清肌酐较基线升高≥1.5倍。
- 持续性AKI定义为持续时间>48小时。
临床怎么用
- PD-L1抑制剂治疗期间应监测AKI,尤其关注合并使用质子泵抑制剂、非甾体抗炎药或抗生素的患者。
局限性
- 回顾性研究设计,疑似PD-L1相关AKI的判定基于病历回顾,可能存在误分类。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Programmed cell death receptor ligand 1 (PD-L1) inhibitors are immune checkpoint inhibitors (ICIs) with a side effect profile that may differ from other classes of ICIs such as those directed against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death 1 receptor (PD-1). Being the more recently approved class of checkpoint inhibitors, there are no studies investigating the frequency, etiology and predictors of acute kidney injury (AKI) in patients receiving PD-L1 inhibitors. METHODS: This was a retrospective cohort study of patients who received PD-L1 inhibitors during 2017 to 2018 in our healthcare system. AKI was defined by a ≥1.5-fold rise in serum creatinine from baseline. The etiology of all cases of sustained AKI (lasting >48 hours) and clinical course were determined by review of electronic health records. RESULTS: The final analysis included 599 patients. Within 12 months of ICI initiation, 104 patients (17%) experienced AKI, and 36 (6%) experienced sustained AKI; however, only 5 (<1%) experienced suspected PD-L1-related AKI. The PD-L1-related AKI occurred a median of 99 days after starting therapy. All patients concurrently received another medication known to cause acute interstitial nephritis (proton pump inhibitors, nonsteroidal anti-inflammatory drugs, or antibiotics) at the time of the suspected PDL1-related AKI. CONCLUSION: Although AKI is common in patients receiving PD-L1 therapy, the incidence of suspected PD-L1-related AKI is low (<1%) and may be less common when compared to other classes of ICIs. This cohort provides further validation that other drugs associated with acute interstitial nephritis may be involved in the pathogenesis of ICI-related AKI.
引用
- Seethapathy H, Zhao S, Strohbehn IA, et al. Incidence and Clinical Features of Immune-Related Acute Kidney Injury in Patients Receiving Programmed Cell Death Ligand-1 Inhibitors. Kidney Int Rep. 2020. PMID: 33102962. doi:10.1016/j.ekir.2020.07.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。